(PA-007) Talquetamab Dosing Strategies in the United States: Real-world Insights from over 250 Patients

Pts with TCE RRMM who received Tal between Aug 9, 2023 (US approval date), and Jan 10, 2025 (last data cut) were identified via the Komodo Healthcare Map™ database. The index date was the date of the first outpatient (OP) Tal SUD (3 mg/1.5 mL) claim or the admission date of an inpatient (IP) Tal encounter. Pts with ≥1 multiple myeloma (MM) diagnosis code before or on index and ≥1 medical or pharmacy claim for Tal were included. Pt characteristics were described for the 6-mo baseline period prior to index. Tal administration, utilization, and time to next treatment (TTNT) were reported descriptively.

Results:

257 pts were identified, with a median (IQR) age of 67.0 (62.0, 74.0) y. 53.3% were male, 64.2% were White, and 66.5% had Medicare. Pts frequently reported hypogammaglobulinemia (45.9%) and infections (45.5%) as comorbidities ≤6 mo prior to index. The median (IQR) duration since MM diagnosis was 6.1 (3.8, 8.1) y. The median (IQR) no. of prior LOTs was 5 (4, 7), and 113 (44.0%) pts had prior penta-drug exposure. Prior exposure to ≥1 commercial BCMA-targeted therapy was reported in 150 (58.4%) pts; overall, 143 (55.6%) pts had prior exposure to T-cell–redirecting therapy. Most pts received Tal monotherapy (n=232; 90.3%), followed by those who received Tal with teclistamab (n=4; 1.6%), pomalidomide (n=4; 1.6%), or other agents. Tal SUD was received IP by 170 (66.1%) pts, OP by 76 (29.6%) pts, and hybrid (IP+OP) by 10 (3.9%) pts. Among 152 pts on QW or Q2W dosing with ≥3 doses post-SUD, 56 (36.8%) switched to every 4 weeks (Q4W) dosing or LFD (median time to switch, 4.7 mo). At the end of follow-up, among pts with ≥3 doses after SUD, 24/52 (46.2%) initially on QW dosing switched to Q2W dosing, and 11/52 (21.2%) switched to every 3 weeks (Q3W) dosing or LFD, and 28/100 (28.0%) initially on Q2W dosing switched to Q3W or LFD. At the end of follow-up, among 183 pts with ≥3 doses post-SUD, 23 (12.6%), 107 (58.5%), 8 (4.4%), and 27 (14.8%) were on QW, Q2W, Q3W, and Q4W dosing schedules, respectively. 58/257 (22.6%) pts had initiated a next LOT by the end of follow-up. With a median (IQR) follow-up of 5.2 (2.5, 8.2) mo, the median TTNT was not reached.

Conclusions: Pts treated with Tal were heavily pretreated, with 58.4% having prior BCMA-targeted therapy. Most pts received Tal monotherapy, though some received Tal-based combinations. One third of pts received SUD in an OP setting. Q2W was the most common dosing schedule, with some pts switching to LFD. TTNT data suggest Tal was effective in a RW setting.